Catalog

c-Met c-Met

Inhibitors

Cat.No.	Name	Information
M6253	Savolitinib	Savolitinib (volitinib, AZD6094, HMPL-504) is a novel, potent, and selective MET inhibitor currently in clinical development in various indications, including PRCC. The IC50 values of this compound for c-Met and p-Met are 5 nM and 3 nM, respectively. It shows exquisite selectivity for c-Met over 274 kinase.
M5310	AMG 337	AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the MET receptor.
M5234	S49076	S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nmol/L.
M4966	DCC2701	Altiratinib(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro.
M3515	MK-2461	MK-2461 is a potent, multi-targeted inhibitor for c-Met(WT/mutants) with IC50 of 0.4-2.5 nM, less potent to Ron, Flt1; 8- to 30-fold greater selectivity of c-Met targets versus FGFR1, FGFR2, FGFR3, PDGFRβ, KDR, Flt3, Flt4, TrkA, and TrkB.
M3396	NVP-BVU972	NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.
M2665	EMD 1214063	EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.
M2080	INCB28060	INCB28060 is a novel inhibitor of c-MET kinase with IC50 of 0.13 nM.
M1922	MGCD265	MGCD265 is a novel multitargeted receptor tyrosine kinase (RTK) inhibitor that targets the mesenchymal epithelial transition (c-Met) and the vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2, and VEGFR3).
M1901	Golvatinib	Golvatinib (E7050) is an orally bioavailable dual kinase inhibitor of c-Met and VEGFR-2 tyrosine kinases with potential antineoplastic activity.
M1899	PHA-665752	PHA-665752 is a selective small molecule c-MET inhibitor (Ki of 4 nM, IC50 of 9 nM).
M1890	SU11274	SU11274 is a selective c-Met inhibitor (IC50 = 0.01 μM in vitro).
M1811	ARQ-197	ARQ-197 (Tivantinib) is a selective and oral small-molecule inhibitor of c-Met with a minimal IC50 value of 0.1 μM.
M1793	JNJ-38877605	JNJ-38877605 is a small-molecule, ATP-competitive inhibitor of the catalytic activity of c-Met with an IC50 of 4 nM.
M1777	SGX523	SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.
M1766	PF-04217903	PF-04217903 (PF-4217903) is a novel ATP-competitive small molecule inhibitor of c-Met kinases with the IC50 values from 3.1 nM to142 nM.
M1765	PF-2341066	PF-2341066 (Crizotinib) is a potent, orally bioavailable, ATP-competitive small-molecule inhibitor of c-Met kinase and ALK (anaplastic lymphoma kinase) with IC50 values to be 4 and 25 nM for C-Met and ALK resepectively.
M1758	Foretinib	Foretinib (XL880, GSK1363089) is a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2 (VEGFR2) with IC50 value of 0.4 nM for c-MET.
M1757	XL-184	XL184 is a small molecule inhibits multiple receptor tyrosine kinases, specifically MET and VEGFR2 with IC50 values of 0.035 and 1.8 nM for VEGFR2 and Met respectively.
M1745	AMG-458	AMG-458 (AMG458) is a potent, selective inhibitor of c-Met and a receptor tyrosine kinase that is often deregulated in cancer.
M1683	BMS 794833	BMS-794833 is a potent ATP competitive Met/VEGFR-2 kinase inhibitor.
M1682	BMS-777607	BMS-777607 is a selective and potent small-molecule met kinase inhibitor with an IC50 of < 0.1μmol/L.
M1647	AMG-208	AMG-208 is a potent small molecular inhibitor c-Met with an IC50 of 9.3 nM.

Signaling Pathways

Product Type

c-Met c-Met

Get to Know Us

Customer Support

Resources

Contact Us